Burger Quick Service - Thriving And Turnkey

Our client has an innovative blockchain platform that operates as a digital marketplace where users can create coins and smart contracts to trade assets, goods, and services using a digitally encrypted, peer-to-peer blockchain exchange system. With our client's platform, users can create, transact, and destroy any digital asset or smart contract in their personal E-Vault utilizing the Ethereum blockchain. In short, our client's platform essentially replaces traditional dependency upon third-party market vendors, such as banks, to make transactions or legally binding contracts. Our client's platform provides a unique capacity for users to easily create digital assets of their choosing to trade in a digital marketplace. With the addition of smart contracts, to provide functions such as mint/burn coin, automate interest rates, collateralize smart contracts, and much more. The value of an asset created by each user is set by the market value. The asset itself may be tangible, for example, a gold-backed digital coin or as intangible like time, such as volunteer or billable hours. Our client's software is run by a hybrid platform/blockchain Decentralized Autonomous Organization (DAO). There are 300 main Spartan Nodes that verify all transactions using similar technology to Solana's quick blockchain speeds by predesignating which node will solve which block. This allows more than 100,000 transactions per second making our client's software the fastest blockchain layer 2 solution that could easily compete with Visa/Mastercard along with the P2P transactions being free! Anyone can also download a node from our client that has the full history and syncs through the blockchain instantly but does not verify any transactions like the main 300 Spartan nodes do. Top 10 Features: 1. Decentralized Exchange w/ over 1,700+ coins 2. Lightning & (soon to be) Raiden Network offers FREE instant transactions 3. Create advanced ERC-20 tokens with imbedded DeFi smart contracts 4. Register ANY real world item as NFT on ETH 5. Create vital records such as birth certificates or last will 6. GNEISS network allows free text and soon free audio/video calls 7. History gives the ENTIRE transaction history for an Evault 8. Verify identity using BasisID with top biometrics in the world and (here soon) credit score 9. Coming soon - DeFi copy of AAVE and margin trading using it 10. Coming later - Multisig Wallets, DAOs, Airdrop, Voting, Swap, Betting, BTC & ETH block inscription) Our client's software is 'ready to go;' and is operating with customers and cash flow. NDA is required to secure comprehensive Confidential Information Memorandum (CIM). Detailed Information Facilities: N/A Growth & Expansion: Unlimited world wide. Financing: Sellers will consider, BitCoin preferred Support & Training: As needed specific terms for transition support can be negotiated. The Seller wishes to facilitate a successful and smooth transfer of the Business. Reason for selling: Expansion.

Our client developed and operates a multi-market high-demand system capable of identifying criminal subjects in seconds. Access to the cloud-based software is subscription-based with packages ranging from $35,000 to $300,000 annually. The system generates recurring revenue from major retailers. Our client's database is fed with crime and criminal data from over 28,000 sources that update and add new data to their system every day. A global technology agreement was recently signed by a major worldwide electronics manufacturer to integrate our client's system. This significant agreement with the major worldwide electronics manufacturer expands the system from single-enterprise sales to mass-market injection via this new customer's global customer base. The enterprise was designed to bridge the long-standing gap between surveillance video and subject identification and create a next-generation system for subject intelligence. The founder tells us: 'We spent significant time and resources to identify over 28,000 data source points and go through the process to obtain, extract, scrub, and continually update records. Our system and process continued to rapidly develop, allowing further increases in data digestion while completely automating the process. We remain the largest private database of criminals in the world. We developed a multi-market high-demand system capable of identifying criminal subjects in seconds. Whether identifying subjects from surveillance video, home security cameras, video doorbell cameras, or conducting compliance and risk mitigation, our solution and its 70 million+ database is a market-first product with no competition and is used by a variety of Fortune 500 blue-chip customers. The signing of a major worldwide electronics manufacturer to a global technology partnership will add our system to their security products, creating a mass-market injection and significant ARR stream.' With a sales, marketing, and business development team comprised of only 2 people, our client focused initially on penetrating the difficult and highly competitive market of loss prevention within Fortune 500 retailers. After the proprietary system demonstrated a successful track record in identifying subjects and deterring criminal activity, our client gained immediate visibility and has since gained nearly a dozen of the world's largest retailers as clients. Our client has disrupted antiquated identification processes within several of the largest markets, attracting the attention of global manufacturers such as the major worldwide electronics manufacturer's willing to integrate their technology. Our client developed a SaaS system, which provides its '4 I's' Intelligence, Information, Investigation, and Identification. The SaaS is a completed system and is fed with crime and criminal data from over 28,000 sources that update and add new data to the system every day. Access to the cloud-based software is subscription-based with packages ranging from $35,000 to $300,000 annually. Our client's technology has been implemented by many of the largest companies in the world and is currently being integrated by one of the largest technology manufacturers in the world. The strategy is effective, and the reach of the technology is poised to be further expanded. Our client invented and made operational multiple processes and new technology. The system is not only completed and automated, but also proven in the marketplace. One of the achievements worthy of note is that our client's system was responsible for the largest Organized Retail Crime bust in US history. Our client's core competencies and strengths include the highly developed system with ownership of the largest private database of criminal subjects in the world, existing blue-chip customers, a global technology contract with a major worldwide electronics manufacturer, and a technology platform that is extremely valuable in multiple other markets that have not yet been approached. Our client's Intelligence obtains its database data from over 28,000 county, state, federal, and regulatory agency sources. Our client has automated the data digestion process to upload new records, and search/verify changed records several times per day. Once new and or changed data is recognized, an automated process will retrieve the data, categorize, and then implement into our client's system. Our client owns all processes, and websites which they will transfer in full to a buyer. Our client's 'ready to go,' profitable tech, and relationships will enable a buyer to be up and running immediately. NDA is required {LINK ABOVE} to secure comprehensive Confidential Information Memorandum (CIM) crafted by ProNova Partners. Detailed Information Facilities: N/A Growth & Expansion: See the CIM for details Financing: Offers and investment will be considered Support & Training: As needed specific terms for transition support can be negotiated. The Seller wishes to facilitate a successful and smooth transfer of the Business. Reason for Selling: To allow the business to rapidly expand world-wide

Patented Universal Tumor-Targeting Drug Delivery Platform Co. This pharmaceutical company has developed and patented a universal tumor-targeting drug-delivery platform that can improve the safety and efficacy of many existing chemo treatments, with the ability to target numerous different types of cancer. The technology encapsulates existing FDA-approved drugs inside lipid nanoparticles (liposomes or emulsions) coated with patented human-sourced antinuclear antibodies (ANA). The lipid nanoparticle provides long-term storage stability of the drug and controlled release of the drug over time at body-temperature, and is expected to improve the safety and efficacy profile of the drug, including passive accumulation at the tumor while not harming normal tissues. The Company's ANA, sourced from lupus patients, binds to nuclear material present in abundance in areas of necrosis (dead / ruptured cells) present in and around all solid tumors, thus anchoring the drug-filled nanoparticles at the tumor where the nanoparticle is designed to slowly release the drug directly on the tumor for more effect. As the Company's ANA is not tumor-marker specific, but rather targets necrosis present in solid tumors, the technology is designed to "universally" target many different types of cancer including breast cancer, lung, ovarian, colon, prostate, etc., as well as rare childhood cancers. The Company completed a successful proof-of-concept study at Children's Hospital using Ewing's Sarcoma transplanted in immunodeficient mice. Treatment with the Company's forumlation significantly inhibited tumor growth and extended survival times compared to control mice receiving no treatment or treatment with plain liposomal doxorubicin. The Company has been granted Orphan Drug Designation by the FDA on 2 of the lead drug formulations, providing FDA fee waivers, priority review, and 7-years exclusivity upon market approval. The orphan pathway also enables the potential for New Drug Approval after successful completion of Phase 2 studies, with Phase III data collected while in the market, thus significantly lowering the time and cost to market approval. This same drug inside the Company's tumor targeting delivery system will likely have potential to treat other pediatric cancers, and/or cancers in larger adult populations. As the Company's platform and ANA has the potential to improve the safety and efficacy of many existing FDA approved drugs or even compounds in development, the Company anticipates the potential for multiple licensing agreements with multiple pharmaceutical companies seeking to improve their existing portfolio and extend patient life as they advance into clinical stage. And as it may be possible to file for New Drug Approval following successful Phase II studies, the Company anticipates licensing potential at early clinical stage. Multiple exit opportunities exist with high impact & high ROI. The Company is seeking a supportive capital partner to maintain momentum up to $20M. Funding will be used to advance the lead drug through formal Investigational New Drug enabling studies towards New Drug Approval; estimating $3-5 Million now to advance into clinical studies. Preclinical / animal studies estimate ($3 - 5 Million and 12-18 months); follwed by potential combined Phase I-II clinical study in a rare cancer (approximately 2-3 years and $10M) to potential New Drug Approval, plus additional capital to advance additional drugs in the pipeline simultaneously, thus adding tremendous value to the Company's valuation. Valuations of pharma companies often exceed $100 Million valuation at Phase I (approx. 18 months), and New Drug Approval can exceed valuations above $1 Billion. The Company has numerous, improved high-impact cancer drugs advancing with proper support. NDA is required for comprehensive Confidential Information Memorandum crafted by ProNova Partners. Detailed Information Competition: Trying to improve existing therapies and develop novel approaches to hard to treat cancers. Growth & Expansion: Huge market potential. Financing: If the price and deal structure is right. Support & Training: Transition team included. Reason for Selling: Seeking supportive capital partners to take to the next level(s). .

This established LLC is offering its proprietary organic dough mixture for sale. A trademark is in place. The creator/owner is a lifelong baker and began experiencing health-related gut issues, as millions of people do. In response, she embarked on a research journey and sourced products from everywhere possible to make a perfect 100% clean, plant-based, organic pizza dough. She wanted to provide pesticide-free dough that could last longer in the fridge, that could take the heat without burning to a crisp and could be boiled, fried, baked, and grilled. She created a dough that could be used every day, in a variety of ways, that wouldn't make you sick. In other words, eating clean, organic dough like the Europeans! Thus, the Company was born! Currently offered in over 300 grocery stores, in both frozen and dry mixes, in a variety of flavors, at a very competitive price point. NDA is required to secure a comprehensive Confidential Information Memorandum (CIM) crafted by ProNova Partners. Detailed Information: organic yeast, no chemicals Facilities: none Not applicable with this book. Competition: Other health food-based dough mixes that typically are not organic and sell at a higher price point. Growth & Expansion: Unlimited room for expansion and growth in brick-and-mortar stores, as well as online sales and wholesale opportunities. Financing: TBD if structure and terms are acceptable. Royalties are of interest. Support & Training: To ensure a smooth transition and ongoing success the Sellers will work with a buyer as needed for three months, as an on-call consultant, or as negotiated. The seller will introduce the current production/packaging vendor relationship. Reason for Selling: The Seller has developed and runs another business, and is looking to focus her efforts there.

Our client is a world leader in iris recognition technology with a large production capacity based in USA. They are a multinational corporation with a robust track record of selling its best-selling, award winning technology products worldwide. Clients include the UN, the US Department of Homeland Security, US Navy, US Marine Corps, the governments of India the Philippines, Kenya, and in the private Sector Northrop Grumman, InCadence and numerous others. The company has and continues to develop an ever-increasing range of technical applications for its products in a very large and rapidly growing market. Applications range from numerous physical security applications to blockchain and cryptocurrency applications. This firm owns 28 patents (24 registered and 4 pending) for its proprietary "iris matching algorithm, iris recognition in bright outdoors under sunlight" technology and security technology. Our client also has world-leading iris recognition technology to crypto wallet, which dramatically improves the security and convenience of digital assets on blockchain. In addition to multiple patents, our client also owns 10 trademarks. Our client's iris recognition algorithm was evaluated as the world's best technology at IREX I of NIST in the USA, and its excellence has been proven. They are one of few companies to provide a complete solution including SW and HW from iris image scanner to matching SDK on server with the world's best technology. This business has global references for the National ID projects of the Indian and Philippine governments They achieved the No.1 market share, including UN-affiliated organizations such as UNHCR and WFP, and these markets are expanding worldwide. Our client's tech and related device is the only iris camera system satisfying MOSIP SBI 2.0 requirements for authentication (many countries are utilizing the MOSIP platform for their National ID systems). Our client's unique and powerful technologies are registered and protected by global patents, enabling stable business development and expansion. The company offers a total data infrastructure solution (large or small data requirements) for Web 3.0 (Web 3.0 is the approach for a new iteration of the World Wide Web which incorporates concepts such as decentralization, blockchain technologies, and token-based economics). Their technologies are based on Blockchain, IPFS, and distributed storage of private keys (IPFS is a distributed file system that seeks to connect all computing devices with the same system of files. This means data can be securely shared for Know Your Customer and Anti-Money Laundering (KYC and AML) needs. This meets information sharing protocols between service providers and will lead to a new and open data economy. The ramifications are complete security for Bank information, Financial Transaction Data, Driving Data, SNS Contents, Health Information, Government/Education Certification, Insurance Information in short data stemming from virtually any source. Confidential Information Memorandum (CIM) is available upon receipt of our short online NDA. Financing: If the price and deal structure is right. Support & Training: Provided at no charge to enable a smooth transition Reason for Selling: World-wide expansion

This profitable Company is a unique California medical network that can be customized to the needs of each individual client. The Company has years of experience in PPO. The business model generates recurring revenue and the technology allows the subscribing clients to customize the network to fit their own needs. The Company also offers several re-pricing options to payers. The Company reviews provider performance to assure compliance with the network's evidence-based treatment guidelines, improving outcomes and offers metrics germane to the medical treatment within the network, allowing payers to monitor performance. The Company is a resource for Group Medical Insurance Providers and Payers, and for Workers Comp Payers to create a custom network of highly qualified medical providers, specific to California. The Company's network and technology allow Payers and Employers to tailor their network to their own specific needs. The payers subscribe to the Company's network generating recurring revenue for the Company. NOTE: This is a re-listing of a major purchase opportunity for a rapidly expanding, profitable California medical network. The initial response to the original listing of this opportunity was huge. A large investment group signed a Letter of Intent To Purchase early on, thus removing the opportunity from the marketplace. The holder of the LOI, following numerous delays over many months, was unable to proceed due to unexpected internal problems separate from their signing the LOI or their completed due diligence. Therefore, this terrific opportunity is now again available for purchase. Our Client's business and profits continue to expand. They have re-listed this purchase opportunity at $3M (USD). This sale price, based on current revenues, growth and profits, should be recovered by a Buyer in short order. Please do not respond to this opportunity unless you will provide proof of funds prior to any demos or negotiations; i.e. the capability to make an acquisition of $3M dollar (USD). The Seller only wishes to work with interested Buyers who, once they are satisfied with their due diligence, are prepared to proceed immediately. We do ask for your understanding in these regards as our initial listing generated a very high volume of responses. NDA is required to secure first round of comprehensive Confidential Information Memorandum (CIM) crafted by ProNova Partners. Facilities: Current rent is $1975 per month for the 1050 sq ft space. Many staff currently work from home, and some have remained in the office space in Tracy, California. Current lease extends through January 31, 2021, so the Buyer may choose to keep this office space or move the Business. The current space allows for social distancing and COVID compliance for those staff who continue to work in the office and not from home. Competition: This Company is unique in the industry and competes against large national players. The Company beats the competition by providing a higher level of customer service, customization of medical provider networks, and competes on price. Growth & Expansion: The Sellers have grown the business to its current level with a slim 'guerilla' marketing budget. An ideal Buyer would have a budget for marketing and advertising, as well as for staffing to handle more leads. With the right Buyer, this Company is primed to grow! Support & Training: As needed. Financing: Available with the right offer Reason for Selling: Retirement.

Our client operates a lean, high-margin B2B lead-generation platform dedicated to the Internet of Things sector. By leveraging a permission-based community of over 60,000 vetted IoT decision-makers and a LinkedIn Group of 20,000+ approved professionals, they deliver turnkey sponsored webinars, white-paper campaigns, and targeted email blasts—providing technology vendors with consistently qualified leads while maintaining minimal overhead through a fully remote, contractor-driven model. NDA is required for comprehensive Confidential Information Memorandum (CIM) crafted by ProNova Partners.

The Company operates in the healthcare technology space with a focus on addressing gaps in dementia and Alzheimer’s care. The company has built an ecosystem where data is collected from caregivers and patients in real-time and pushed into physicians’ EHR/EMR systems to monitor the effectiveness of the prescribed treatment plan. Alzheimer’s Disease and other dementia is the first condition that the platform will be focused on. Its platform supports physicians in managing patients through tools that enable remote monitoring and data collection, allowing for more continuous oversight rather than episodic intervention. The business generates revenue through a combination of public healthcare reimbursements and collaborations with pharmaceutical and research entities. Its model emphasizes integrating digital health solutions into clinical workflows to improve patient tracking and care coordination. The Company’s target users include healthcare providers, caregivers, and researchers working with aging populations impacted by cognitive decline. NDA is required to receive comprehensive Confidential Information Memorandum (CIM) crafted by ProNova Partners.